Skip to Main Content

Paper Details

Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential.
Nat Commun
7
2022
AR, AR enhancer, AR sites, Androgen, Androgen receptor, PCa, androgen, androgen receptor enhancer, human, patient, patients, primary PCa, primary prostate cancers, primary prostate tumors, prostate cancer, tumor
Author NameAffiliation
Tesa M SeversonOncode Institute, Netherlands Cancer Institute
Tesa M SeversonOncode Institute, Netherlands Cancer Institute
Sylvan C BacaThe Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute
Bogdan PasaniucDavid Geffen School of Medicine, University of California Los Angeles
Bogdan PasaniucDavid Geffen School of Medicine, University of California Los Angeles
Matthew L FreedmanThe Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute
Matthew L FreedmanThe Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute
Matthew L FreedmanThe Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute
Matthew L FreedmanThe Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute
Lodewyk F A WesselsOncode Institute, Netherlands Cancer Institute
Andries M BergmanOncode Institute, Netherlands Cancer Institute
Andries M BergmanNetherlands Cancer Institute
Wilbert ZwartOncode Institute, Netherlands Cancer Institute
Wilbert ZwartLaboratory of Chemical Biology and Institute for Complex Molecular Systems, Eindhoven University of Technology
  • 1 - 14

Datasets

Release 1.2